Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Julian who wrote (987)	8/2/2000 12:47:28 PM
From: Ian@SI	Read Replies (1) \| Respond to of 1321

Julian, Many thanks for the NB earnings summary report. I especially liked the paragraph, "...We have looked at three different approaches to choosing an appropriate multiple for QLT in the context of the current market. All three methods indicate QLT is undervalued compared to U.S. peers and yield target prices that range from $180 to $220 two years from now. A 20% discount would yield a one-year target of $150 to $165. ..." Given that both QLT and Christine are prone to lowballing, a triple from today's price within 2 years seems almost probable. I picked up a trading position just prior to the FDA Panel recommendation last year. I broke my rules luckily and made it a core holding rather than realize the quick profit. Those shares are now well over double what I paid for them. Seeing Christine's analyses has been most helpful in ignoring some of the noise coming out of some of the intellectually challenged analysts covering this company. Best regards, Ian.